Histogenics Reports Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2015

Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the year ended December 31, 2015.
Adam Gridley, President and Chief Executive Officer of Histogenics stated:

2015 was a year of transition for Histogenics.  We made significant progress toward our long-term business objectives by strengthening our management team with several key hires, changing and augmenting our approach to recruiting the NeoCart Phase 3 clinical trial and continuing to advance both the technical transfer activities for our manufacturing operations and our collaboration with Intrexon. We believe that the recruiting and investigator changes we put in place for the NeoCart Phase 3 clinical trial are having a positive impact on our enrollment rates and remain confident that we will complete enrollment by the end of the second quarter of 2017.

Gridley added:
The changes we made in 2015 to our clinical trial strategy and management team provide a solid foundation for us to complete our NeoCart Phase 3 clinical trial, and we are now focused on execution of our objectives for 2016,” stated Mr. Gridley.  “We are pleased with the enrollment rates we have seen over the last few months in the NeoCart Phase 3 clinical trial as well as with the progress we have made on the other aspects of the NeoCart development program.  We look forward to a successful year in 2016
Click here to view the full press release.